Privia Health Group (PRVA) just posted its third-quarter results, reporting a 33% increase in revenue and surpassing Wall Street estimates. Despite this positive outcome, guidance for the full year remained cautious.
See our latest analysis for Privia Health Group.
Shares of Privia Health Group have seen respectable momentum this year, with a 24% year-to-date share price return and a 13.5% total shareholder return over the past twelve months. Recent volatility, driven by mixed reactions to management’s cautious outlook despite impressive top-line growth, shows that investors are weighing the company’s expanding footprint against ongoing uncertainties.
If this latest earnings move has you watching healthcare stocks, you may want to discover the standout names featured in our See the full list for free..
As the company trades at a notable discount to analyst price targets despite strong results, investors are left questioning whether Privia Health is undervalued or if the market has already priced in all its future growth potential.
With Privia Health Group’s fair value narrative set at $31.11, well above the last close of $24.37, the latest update points to significant upside potential, supported by new guidance and a higher analyst price target. A closer look at the narrative exposes the assumptions driving this valuation.
Bullish analysts highlight the impact of Privia Health’s successful participation in the Medicare Shared Savings Program, which supports higher revenue forecasts and increases confidence in future growth prospects. The company’s upward revision of 2025 EBITDA guidance, now targeted at $113 million to $116 million, indicates improved operational execution and efficiency. This development enhances the outlook for margin expansion.
Want to see the bold assumptions setting Privia apart from its peers? Uncover the future profit margins, growth rates, and elusive targets that could define the company’s next act. The numbers behind this valuation might surprise you, so see what the narrative leaves out.
Result: Fair Value of $31.11 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, continued healthcare consolidation and regulatory shifts could disrupt Privia’s growth trajectory, which may challenge the bullish outlook surrounding its recent performance.
Find out about the key risks to this Privia Health Group narrative.
Looking beyond multiples, the SWS DCF model paints an even more bullish picture for Privia Health. With a calculated fair value of $38.22 per share, which is well above both the recent price and analyst targets, the DCF approach suggests the market could be missing significant long-term upside. How much weight should investors place on this richer scenario?
